London-based Vicebio Secures $100M Series B to Advance Cost-Effective Vaccines

Sep 24, 2024, 09:51 AM

Vicebio, a London-based biotech startup, has successfully raised $100 million in a Series B financing round. The funding will be used to advance its next-generation vaccine candidates into Phase 1 clinical trials. The vaccines aim to be cost-effective and target respiratory viruses such as RSV and hMPV. The financing round saw participation from investors including TCGX, G. Sachs Alternatives, Avoro, venBio, uniQuest, and Medicxi.